ClinicalTrials.gg
RecruitingNCT06756139Updated Jul 1, 2025

Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia

An interventional study of cognitive behavioural therapy mobile application and Flupentixol and Melitracen Tablets in Functional Dyspepsia, Self-help Mobile Cognitive Behavioral Therapy and Antipsychotic Drug, sponsored by Air Force Military Medical University, China. Recruiting at 7 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Air Force Military Medical University, China · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Dyspepsia with a site in China — 9 open to participants now, 10 under way, none of them phase 3. Dyspepsia · China.

Planned enrollment
40th of 46
88 · median 218
Started
2024
with 3 others
No phase
17 of 58
4 open now
Registered
50th of 58
by date
Lead sponsor
8 of 58
Air Force Military Medical University, China

Among the 58 studies in Dyspepsia with a site in China, this one is the 40th largest by planned enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2024, is one of 17 with no phase, and was the 50th registered.

Dyspepsia

373 studies on the registry are indexed under Dyspepsia; 67 are open to participants now.

Browse Dyspepsia studies →

Open to participants now

9 of the 58 studies in Dyspepsia with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Dyspepsia with a site in China, or all of them as a file.
02

Study summary

Functional dyspepsia (FD) is a common gastrointestinal disease, which is associated with decreased life quality and increased medical cost. Antipsychotic drugs were demonstrated to be effective in relieving symptoms in FD patients, especially for patients with refractory FD. However, the use of those drugs was associated with obvious adverse events. Cognitive behavioral therapy (CBT) has extensive applications and exhibited potential treatment effects in clinical practices, especially for treating anxiety, depression, pain or stress disorders. Several previous RCT studies have confirmed the effects of psychological intervention on improving dyspepsia in FD patients. Our hypothesis was that 8-week smartphone-based CBT would be non-inferior to conventional pharmacotherapy in reducing FD-related symptoms in patients with refactory FD.

03

Conditions studied

  • Functional Dyspepsia
  • Self-help Mobile Cognitive Behavioral Therapy
  • Antipsychotic Drug

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80
  2. functional dyspepsia (patients with Rome IV functional dyspepsia remained symptomatic after treatment of 8 weeks of proton pump inhibitor and 4 weeks of prokinetics)
  3. Negative or unrelated-to-FD symptom findings of gastroscopy, upper abdominal ultrasound, Hp test and routine blood tests within the past 1 year.

Exclusion criteria

Exclusion Criteria:

  1. Severe mental illness (PHQ-9 ≥20 or GAD-7 ≥15) or suicidal ideation;
  2. Known hp infection, active gastrointestinal peptic ulcer, cholecystitis, gallstones, suspected or known bowel obstruction, gastroparesis, major gastrointestinal surgery etc.;
  3. Known or suspected malignant tumor, significant heart/brain/liver/kidney diseases, obvious hematologic abnormalities or endocrine diseases etc., which may be -related to FD symptoms;
  4. Known or suspected drug-related FD (e.g.NSAIDs-related FD);
  5. Unable to access to mobile networks or unable to manage mobile APP properly.
  6. Allergy or other contradictions to flupenthixol or melitracen
  7. Taking any antipsychotics drugs or CBT interference within 12 weeks
  8. Pregnant or lactating women;
  9. Unable to provide .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    Cognitive behavioural therapy mobile application

    All patients received standard first-line treatment for FD, including PPIs and/or prokinetics, which was at the discretion of physicians. Additionally, patients underwent mobile app (named LotusHope)-based CBT to learn or practice the skills of acceptance, cognition, values, goal-setting and behavioral exercises. It takes approximately 15-20 minutes to complete one CBT treatment per day. The mobile app-based interference will last for 8 weeks.

    Procedure: cognitive behavioural therapy mobile application

  • Placebo comparator
    Flupentixol and Melitracen Tablets

    All patients received standard first-line treatment for FD, including PPIs and/or prokinetics, which was at the discretion of physicians. Patients also took 1-2 tablets of deanxit (a compound preparation of tricyclic antidepressant (melitracen) and antipsychotic drug(flupentixol)) orally for 8 weeks.

    Drug: Flupentixol and Melitracen Tablets

Interventions

  • Procedurecognitive behavioural therapy mobile application

    The CBT mobile application enables patients to conduct cognitive therapy independently.

  • DrugFlupentixol and Melitracen Tablets

    patients take Flupentixol and Melitracen Tablets

06

What researchers measure

Primary outcomes

  1. 1. The primary endpoint was the change in GOSS scores from baseline to week 8 after treatment.

    GOSS (7-point Global Overall Symptom Scale) is a scoring system composed of ten primary symptom ratings. The main symptoms include upper abdominal pain, early satiety, postprandial fullness discomfort, bloating, nausea, acid reflux, heartburn, excessive belching, upper abdominal discomfort, and other upper abdominal discomforts. Each item is scored from 1 to 7, with 7 representing the most severe symptom. The total score is the sum of the scores for the ten symptoms.

    Time frame: 8weeks

Secondary outcomes

  1. 5-Likert score

    The patients were interviewed to answer the question "Compared with the condition before receiving treatment, how about your gut condition now?" The following questions were chosen: (1) extremely worse, (2) slightly worse, (3) same as before, (4) slightly better, (5) much better.

    Time frame: 4 weeks, 8weeks, 12 weeks

  2. Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10)

    PROMIS (Patient-Reported Outcomes Measurement Information System) Global-10, also known as the Global Quality of Life Score, is a patient-reported questionnaire consisting of 10 items. The responses are rated on a scale of 1-5 (with an additional 0-10 rating scale for a single item), and the final outputs are two standardized scores: the global physical health score and the global mental health score. Higher scores indicate better quality of life for the patient.

    Time frame: 4 weeks, 8weeks, 12 weeks

  3. GOSS score

    GOSS (7-point Global Overall Symptom Scale) is a scoring system composed of ten primary symptom ratings. The main symptoms include upper abdominal pain, early satiety, postprandial fullness discomfort, bloating, nausea, acid reflux, heartburn, excessive belching, upper abdominal discomfort, and other upper abdominal discomforts. Each item is scored from 1 to 7, with 7 representing the most severe symptom. The total score is the sum of the scores for the ten symptoms.

    Time frame: 4 weeks, 8weeks, 12 weeks

  4. Short Form of Nepean Dyspepsia Index (SF-NDI)

    The SF-NDI consists of 10 questions regarding the effects of dyspepsia symptoms ("stomach problems") on different aspects of life (tension, interference with daily activities, eating/drinking, knowledge/control, and work/study). Each response can be from 1 (not at all affected) to 5 (extremely affected), or 0 (N/A), for a total summed score out of 50.

    Time frame: 4 weeks, 8weeks, 12 weeks

  5. Patient Health Questionnaire-9(PHQ-9)

    For the PHQ-9: Scores of 0-4 indicate "Minimal Depression," 5-9 indicate "Mild Depression," 10-14 indicate "Moderate Depression," 15-19 indicate "Moderately Severe Depression," and 20-27 indicate "Severe Depression."

    Time frame: 4 weeks, 8weeks, 12 weeks

  6. Generalized Anxiety Disorder-7(GAD-7)

    For the GAD-7: Scores of 0-4 indicate "Minimal Anxiety," 5-9 indicate "Mild Anxiety," 10-14 indicate "Moderate Anxiety," and 15-21 indicate "Severe Anxiety."

    Time frame: 4 weeks, 8weeks, 12 weeks

  7. HAM-D17

    The Hamilton Depression Rating Scale, 17-item version (HAM-D17) consists of 17 items, each of which is rated on a scale of 0 to 2 or 0 to 4, depending on the severity of the symptom. For scoring, a HAM-D17 score of 0-7 is generally accepted as within the normal range or in clinical remission, while a score of 20 or higher indicates at least moderate severity and is often required for entry into a clinical trial.

    Time frame: 4 weeks, 8weeks, 12 weeks

  8. HAMA-14A

    The Hamilton Anxiety Rating Scale (HAMA-14A) probes 14 parameters, each scored on a 5-point scale ranging from 0 (not present) to 4 (severe). For scoring, a HAMA-14A score of 14-17 indicates mild anxiety, 18-24 indicates moderate anxiety, and 25-30 indicates severe anxiety.

    Time frame: 4 weeks, 8weeks, 12 weeks

  9. Treatment adherence

    The treatment adherence to the treatment will be evaluated by the completion of drug or the core modules of APP.

    Time frame: 12 weeks

07

Study locations

5 of 7 sites recruiting
  • Hainan General Hospital (Hainan Affifiliated Hospital ofHainan Medical University)
    Haikou, Hainan 570000, China
    Recruiting
    • Na Liu, MD, Ph.D · Contact
  • Air Force Military Medical University, China
    Xi'an, Shaanxi 710032, China
    Recruiting
  • Shaanxi Second People's Hospital
    Xi'an, Shaanxi 710032, China
    Recruiting
    • Limei Wang, MD, Ph.D · Contact
  • Tangdu Hospital
    Xi'an, Shaanxi 710032, China
    Not yet recruiting
    • Zhenxiong Liu, MD, Ph.D · Contact
  • Xi'an 986 Hospital
    Xi'an, Shaanxi 710032, China
    Recruiting
    • Jun Wang, MD, Ph.D · Contact
  • Xi'an People's Hospital
    Xi'an, Shaanxi 710032, China
    Not yet recruiting
    • Rui Huang, MD, Ph.D · Contact
  • Mianyang Third Hospital
    Mianyang, Sichuan 621000, China
    Recruiting
    • Long Zou, Ph.D · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2025, 12 months after the start.

Of 71 non-industry interventional studies with no phase under Dyspepsia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 28. This study's planned 12 months is below that.

Counting every sponsor, half of 79 studies reached it within 17 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2024
First posted
Jan 1, 2025
StartActual
Nov 1, 2024
Primary completionEst.
Nov 1, 2025
CompletionEst.
Nov 1, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06756139
Collaborators
Xi'an 986 Hospital, Shaanxi Second People's Hospital, Xi'an People's Hospital (Xi'an Fourth Hospital), Tang-Du Hospital, Hainan General Hospital, Mianyang Third Hospital
Responsible party
Yanglin Pan (professor, Air Force Military Medical University, China) — Principal investigator
First posted
Jan 1, 2025
Start date
Nov 1, 2024
Primary completion
Nov 1, 2025 (estimated)
Completion
Nov 1, 2025 (estimated)
Last update
Jul 1, 2025

Study contacts

Yanglin Pan, Professor
Contact
yanglinpan@hotmail.com
13991811225
Xiaoyu Kang, MD, Ph.D
Contact
kangxiaoyu@hotmail.com
15291680602

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion